Gilead Sciences (NASDAQ:GILD) issued an update on its FY20 earnings guidance on Monday morning. The company provided EPS guidance of $6.98-7.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.60. The company issued revenue guidance of $24.3-24.35 billion, compared to the consensus revenue estimate of $22.54 billion.Gilead Sciences also updated its FY 2020
Pre-Market guidance to -0.08-0.02 EPS.
A number of analysts have recently weighed in on the stock. BMO Capital Markets reduced their price target on shares of Gilead Sciences from $64.00 to $62.00 and set a market perform rating for the company in a research note on Wednesday, December 16th. Piper Sandler cut their price target on shares of Gilead Sciences from $84.00 to $80.00 and set an overweight rating on the stock in a report on Tuesday, December 15th. Robert W. Baird upped their price objective on shares of Gilead Sciences from $63.00 to $67.00 and gave the company a neutral rating in a research note on Wednesday, December 16th. Credit Suisse Group dropped their price objective on shares of Gilead Sciences from $70.00 to $65.00 and set a neutral rating on the stock in a research note on Wednesday, December 16th. Finally, Oppenheimer dropped their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set an outperform rating on the stock in a research note on Thursday, December 17th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $92.87.
Shares of Gilead Sciences stock opened at $61.54 on Thursday. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.25 and a quick ratio of 3.15. Gilead Sciences has a fifty-two week low of $56.56 and a fifty-two week high of $85.97. The firm has a fifty day moving average price of $59.86 and a two-hundred day moving average price of $64.79. The company has a market cap of $77.14 billion, a PE ratio of 63.44, a price-to-earnings-growth ratio of 0.70 and a beta of 0.52.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th were paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.42%. The ex-dividend date was Monday, December 14th. Gilead Sciences’s dividend payout ratio is 44.30%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: What is an inverted yield curve?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.